A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Evaluate The Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects Of Subcutaneous Ublituximab Versus Intravenous Ublituximab In Patients With Multiple Sclerosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521127-73-00

Acronym

TG1101-RMS-SC301

Enrollment

Registered

2025-08-19

Start date

2025-09-12

Completion date

Unknown

Last updated

2025-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing forms of Multiple Sclerosis

Brief summary

Commercially confidential information

Detailed description

Proportion of participants with CD19+ B- cell (please ref to the protocol for the full information), Incidence of treatment emergent adverse events (TEAE)

Interventions

DRUGUblituximab

DRUGublituximab

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Commercially confidential information	—

Secondary

Measure	Time frame
Proportion of participants with CD19+ B- cell (please ref to the protocol for the full information), Incidence of treatment emergent adverse events (TEAE)	—

Countries

Bulgaria, Croatia, Czechia, Hungary

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026